H
Harbour BioMed
Biopharmaceutical company developing fully human antibody therapeutics for oncology and immunology
About Harbour BioMed
Harbour BioMed is a global biopharmaceutical company focused on the discovery, development and commercialisation of novel antibody therapeutics for oncology, immunology and other therapeutic areas. Its proprietary Harbour Mice platform generates fully human monoclonal antibodies in two formats - H2L2 and heavy chain only (HCAb) - while the HCAb-based immune cell engagers (HBICE) are designed to deliver tumour-killing effects beyond what traditional combination therapies achieve.
The company combines internal R&D with strategic global collaborations, co-discovery and co-development partnerships, and selective acquisitions. Its platform has been licensed to biopharma partners including BeiGene and Innovent Biologics for fully human monoclonal antibody drug discovery.
Harbour BioMed operates globally, with a presence in the United States, Europe and China, and listed on the Hong Kong Stock Exchange (HKEX: 02142) in December 2020. The company continues to advance a pipeline of novel antibody therapeutics powered by its fully human antibody discovery engine.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
News
Open roles
Harbour BioMed in the Cambridge ecosystem
The Harbour BioMed office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
Legend Capital- ACAdvantech Capital
GIC- C(Cambridge University Endowment Fund (CUEF)
Vertex Holdings- SFSovereign Wealth Funds
- CIChina Life Private Equity Investment
- ZCZheshang Venture Capital
SK Group- ECEfung Capital
- ZCZhejiang University Future Capital
- GFGreater Bay Area Fund
- JCJT New Century
Series B and later7 investors entered at this stage
Hudson Bay Capital Management
OrbiMed- SGShenZhen GTJA Investment Group
Octagon Capital Partners
Sage Partners
Country Garden
AstraZeneca
Source: Dealroom Talent Intelligence.
Patents
89 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Harbour BioMed on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

